Epitalon (10 mg vial) dosage protocol

1. Draw 2 mL of bacteriostatic water with a sterile syringe.
2. Inject it slowly down the inside wall of the vial, not onto the powder, to avoid foaming.
3. Swirl or roll the vial gently until the powder dissolves. Do not shake it.
4. Label it with the date and the volume of water, and refrigerate at 2-8 °C (36-46 °F), away from light.

• Reconstitute: add 2 mL of bacteriostatic water for a 5 mg/mL solution.
• Amounts in the chart: 5 mg each time, by subcutaneous injection, once a day.
• Easy measuring: at 5 mg/mL, one unit (0.01 mL) on a U-100 insulin syringe holds about 50 mcg.
• Storage: freeze-dried, keep it sealed, cold and away from light (frozen for long storage). Once mixed, refrigerate at 2-8 °C and avoid freezing and thawing.

Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modelled on a pineal gland extract and studied mainly by one Russian research group for effects related to ageing. Its evidence is mostly from cells and animals, and it is not FDA-approved.

• Primary calculation: 10 mg made up to 2 mL equals 5 mg/mL.
• Amounts shown: 5 mg per administration. Reported in the research community. It has not been tested as a schedule in human trials.
• Route and frequency: subcutaneous injection, once a day.
• Evidence ceiling: 3 of the 9 studies with a dose in our library were done in people.
• Regulatory status: Not FDA-approved for any use. It was in Category 2 of FDA's compounding bulk substances list (possible significant safety risks); FDA's April 2026 update lists its nomination as withdrawn, which is not an approval.

A 10 mg vial holds 10,000 mcg of Epitalon. Adding 2 mL gives 5 mg/mL, so one U-100 unit (0.01 mL) holds 50 mcg. To get the units for an amount, divide it by 50 mcg. The units are a volume mark on the syringe, not a measure of potency.

• 5 mg: 1 mL, or 100 U-100 units.

Vial coverage by mass: 2 full amounts of 5 mg per vial, before any handling loss.

If a different volume of water is used, every unit figure changes: recalculate with the calculator above.

The human reports we could verify all come from the Khavinson group and give few methodological details in their abstracts:

• Retinitis pigmentosa: the authors reported a positive clinical effect in 90% of patients with degenerative retinal disease, without patient numbers or control details in the abstract (Khavinson 2002).
• Melatonin: in elderly people with low pineal function, epitalon and epithalamin were followed by higher night-time melatonin; the article is in Russian (Korkushko 2007).
• Mortality in elderly people: a long-term study of 266 elderly people reported lower death rates, but it used the extracts epithalamin and thymalin, not epitalon (Khavinson 2003).

Verdict: there is no reliable human evidence that epitalon slows ageing or improves any health outcome. The available reports are small, from the developing group, and not independently replicated.

Every study dose, including animal and cell studies, is in the Epitalon dose table.

Side effects and safety in people are unknown: there are no modern controlled trials, and data on how the body processes it are lacking (Jain 2026). In its compounding review, FDA said compounded epitalon may carry a risk of immune reactions and impurity problems and that it had not identified safety information for the proposed route.

• Product quality: epitalon sold online is not checked by any regulator for identity, purity, dose or sterility. A 2015 report from Belgium's Scientific Institute of Public Health identified epitalon in two illegal pharmaceutical preparations.
• Telomeres and cancer: lengthening telomeres lets cells keep dividing, which is also how cancer cells become immortal. Epitalon lengthened telomeres in breast cancer cell lines (Al-Dulaimi 2025), although a mouse study found fewer leukaemias (Anisimov 2003). The long-term effect in people is unknown.
• Single-group evidence: most data come from the developers, so benefits and safety have not been independently checked.
• Injection risks: any injected product that is not sterile can cause infection or abscesses.

• FDA: Not FDA-approved for any use. It was in Category 2 of FDA's compounding bulk substances list (possible significant safety risks); FDA's April 2026 update lists its nomination as withdrawn, which is not an approval.
• Evidence limits: reported use is not evidence that a schedule works or is safe. Animal doses do not convert to people, and research products are not made or checked for use in people.
• Status checked on: Oct 26, 2026.